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Abstract: Second extracellular loop (ecl2) of the dopamine (DA) D2 receptor is 
an essential part of the binding pocket of dopaminergic ligands. To form a part 
of the ligand-binding surface, it has to fold down into the transmembrane do-
main of the DA receptor. The current study describes the modeling of the D2 
DA receptor ecl2 and its interactions with arylpiperazine ligands. In order to 
model the D2 DA receptor ecl2, several arylpiperazine ligands were used to 
propose a pharmacophore model. D2 DA receptor ecl2 model was built using 
Accelrys Discovery Studio. To test the proposed model, docking analysis was 
performed and key amino acid residues were determined. The proposed recep-
tor–ligand interactions were rationalized and compared with measured binding 
affinities. It is shown that D2 DA receptor ecl2 significantly participates in the 
formation of the receptor–ligand complex through aromatic, hydrophobic and 
polar interaction. Considering them would benefit molecular modeling of G-
protein-coupled receptors (GPCRs) and facilitate the design of novel active 
compounds. 
Keywords: extracellular loop; dopamine; arylpiperazine; molecular modeling; 
GPRC. 
INTRODUCTION 
The catecholamine dopamine (DA) has been associated with many physiolo-
gical functions such as fine movement coordination, cognition, emotion and me-
mory by the mesocortical and mesolimbic reward systems.1 
Alterations in dopaminergic function are involved in the pathogenesis of 
Parkinson’s disease,2 psychomotor diseases and schizophrenia.3 
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The DA receptor system has been aggressively targeted for drug develop-
ment for the treatment of psychiatric illnesses, neurodegeneration, drug abuse, 
and other therapeutic areas.4,5 The DA receptors, belonging to the class of G-
protein-coupled receptors (GPCRs), are found in both the peripheral and central 
nervous system (CNS).3 The D2 DA receptor is a GPCR located on postsynaptic 
dopaminergic neurons that is heavily involved in reward-mediating mesocortico-
limbic pathways. Signaling through D2 DA receptors governs physiological 
functions related to locomotion, hormone production, and drug abuse. D2 DA re-
ceptors are also known targets for antipsychotic drugs used to treat psychomotor 
diseases such as schizophrenia.6 Although the biophysical and pharmacological 
properties of D2 DA receptors have been the subject of a number of studies,7 
many questions remain unresolved due to the lack of three-dimensional structures 
and other experimental limitations. 
An enormous amount of work has been performed toward the development 
of various D2 DA receptor ligands. These efforts yielded a class of compounds 
known as dopaminergic arylpiperazine ligands.8  
The pharmacophore of dopaminergic arylpiperazines has been well studied 
in experiments and molecular simulations.9 Published results and 3D models ex-
plain to some extent the binding mechanism of arylpiperazine to the D2 DA re-
ceptor,10–12 but still a complete understanding of the process is lacking, notably 
in the case of ligands that protrude from the canonical receptor binding site into 
the extracellular loop area. To obtain a better understanding of receptor–ligand 
interactions, a more precise model of the D2 DA receptor is required. 
In this paper, focus will be centered on the extracellular loop area of the D2 
DA receptor, particularly on the E2 loop segment. Considering that the crystal 
structures of D2 DA receptors are not available, in silico methods were used to 
gain further insight into the binding interactions between the extracellular loop 
area of D2 DA receptors and a new series of dopaminergic arylpiperazines. 
EXPERIMENTAL 
Ligand construction 
The 3D structures of the ligands were generated using the Discovery Studio program.12 
Assuming physiological conditions, the basic aliphatic nitrogen atom of the piperazine was 
protonated. The geometry was optimized using the CHARMM force field applying the con-
jugate gradient method until the energy difference between successive cycles was below 
0.0042 kJ mol-1.  
Pharmacophore model generation 
The set of ligands used for pharmacophore generation consisted of the structures shown 
in Tables I and II with their dopamine D2 receptor binding affinities listed. The molecules 
were stored in a molecular database. This database was used as an input in the Discovery 
Studio pharmacophore protocol12. 
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TABLE I. Arylpiperazine ligands showing moderate to high D2 affinity 
No. R Ki / nM 
113 2.9 
213 56.0 
314 CH3SCH2– 15.4 
414 CH3SOCH2– 24.8 
The objective of the pharmacophore protocol is to generate all popular pharmacophore 
queries (with coverage n, typically 90 % or more of all active molecules) considering all pos-
sible discrete geometries with all possible combinations of input query expressions. The phar-
macophore protocol operates on the 3D conformations of the molecules present in the input 
database. In the present study, the Conformations option in Pharmacophore protocol panel 
was set to BEST quality, wherein the rotatable bonds of each molecule were explored syste-
matically to specific torsion angles from a collection of rules. The ring conformations were 
not searched; the chair conformation was assumed preferred as most of the docking runs fi-
nished with the ligands having the ring in the chair conformation.  
Using these features for the determination of the minimal pharmacophore together with 
the enabled alignment of the aromatic ring atoms led to meaningful pharmacophore hypo-
theses. The pharmacophore protocol generated pharmacophores compatible with the minimal 
number of set features. Other parameter values in the pharmacophore protocol panel were kept 
at their default values. The results of the pharmacophore generation were written to an output 
database, which was analyzed further to visualize the appropriate pharmacophore hypothesis. 
The selection of the final hypothesis was based on an overall alignment score and the asso-
ciated pharmacophore features. 
Molecular modeling of D2 DA receptor extracellular loops 
The starting point for molecular modeling was the currently valid loop-less dopamine D2 
receptor model.9 The Discovery Studio program package12 was used to model the sequences 
of D2 DA receptor loops. Missing loops sequences were aligned with the D2 receptor se-
quence and this alignment was supplied along with the 3D coordinates of the existing model 
as an input to the program. A key determinant of the correct orientation of the extracellular 
loops is the constrain imposed by the position of the corresponding receptor helixes and a 
disulfide bond between the ecl2 and the top of the TM domain 3. The Discovery Studio loop 
refining implements protein loop modeling by satisfying these restraints while keeping the 
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existing part of the model fixed. This was followed by spatial constraints that were imposed to 
selected amino acid residues in order to satisfy the pharmacophore hypothesis. In order to ob-
tain a relaxed conformation, the generated models were initially subjected to an energy mini-
mization process using the conjugate gradient method for about 4000 iterations and to 2-ns 
isothermal, constant-volume MD simulation, with CHARMM all-hydrogen amino acid para-
meters in the Discovery Studio program running on a PC.15 To assess the quality of the mi-
nimized models, Proteincheck12 analysis was also undertaken. Initially, several possible mo-
dels were constructed but the best possible model was considered the receptor “energy minima”. 
Docking analysis 
Docking of the selected ligands as presented in Tables I–III was realized by simulated 
annealing using the LIBDOCK module from Discovery Studio. All ligands were docked as 
protonated, using the CHARMM force field. Amino acid residue charges were adjusted when 
needed. The protein-binding site was determined by combining results from experimental data 
and the Discovery Studio bind site analysis module.12 Initial position of the ligand in the bind-
ing site was defined by keeping the protonated nitrogen on the ligand in close proximity to the 
Asp80 of the D2 receptor. After initial ligand placement, no further constraints were applied 
and the docking procedure based on Monte Carlo methodology was performed. Up to 100 
structures were produced in every run and each finally optimized in order to remove steric 
interaction with a gradient limit of 0.0042 kJ mol-1 or 4000 optimization steps. 
TABLE II. The arylpiperazine ligands used in the generation of the pharmacophore model and 
the docking analysis (marked +) 
No. R1 R2 Ki / nM 
516 –CONH(CH2)4– 83±5 
616 –CONH(CH2)4– 84±2 
7+16 –CONH(CH2)4– 75±12 
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TABLE II. Continued 
No. R1 R2 Ki / nM 
8+16 –CONH(CH2)4– 59±9 
916 –CONH(CH2)4– 87±19 
1016 
 
86±1 
1116 –(CH2)4– 45±7 
1217 
 
–CH=CH–CONH–(CH2)4– 13±1 
1317 –CH=CH–CONH–(CH2)4– 20±1 
1417 –CH=CH–CONH–(CH2)4– 23±1 
1517 –CH=CH–CONH–(CH2)4– 37±6 
16+17 –CH=CH–CONH–(CH2)4– 10±0.7 
1717 –CH=CH–CONH–(CH2)4– 14±3 
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TABLE II. Continued 
No. R1 R2 Ki / nM 
18+17 –CH=CH–CONH–(CH2)4– 11±2 
1917 –CH=CH–CONH–(CH2)4– 12±1 
2017 –CH=CH–CONH–(CH2)4– 37±15 
2117 –CONH(CH2)4– 19±1 
2217 –(CH2)4– 50±6 
23+17 –(CH2)4– 40±3 
2418 –CONH–(CH2)4– 37±6 
17+18 –CONH–(CH2)4– 36±4 
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TABLE II. Continued 
No. R1 R2 Ki / nM 
1818 –CONH–(CH2)4– 77±17 
19+18 –CONH–(CH2)4– 21±2 
2818 –CONH–CH2CH=CHCH2– 79±2 
2918 –CONH–CH2CH=CHCH2– 60±7 
3018 –CONH–CH2CHOH–(CH2)2– 52±3 
3119 –CONH–(CH2)4– 55±5 
32+19 –CONH–(CH2)4– 28±6 
3319 –CONH–CH2CH=CHCH2– 69±13 
34+19 –CONH–CH2CH=CHCH2– 48±7 
3519 –CONH–CH2CHOH–(CH2)2– 68±6 
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TABLE II. Continued 
No. R1 R2 Ki / nM 
36+20 –CONH–(CH2)4– 15±1 
37+21 –CONH–(CH2)3– 11±1 
TABLE III. Arylpiperazine ligands used in the testing of the receptor model 
No. R1 R2 Ki / nM 
3819 –CONH(CH2)4– 83±5 
3916 –CONH(CH2)4– 200±30 
4022 
 
518±193 
The obtained docked structures were examined, and those with the lowest total energy 
were further filtered to obtain docking structures with the best ligand fit. We selected struc-
tures based on the following criteria: lowest total energy of the complex, shortest salt bridge 
formed between Asp80 of the D2 receptor and the proton on nitrogen, chair conformation of 
arylpiperazine ring and the aryl part of the molecule positioned in the rear hydrophobic pocket 
of the receptor were selected. After the initial criterion was satisfied, the second step was exa-
mination of different interactions that could be formed between the receptor and ligand (hyd-
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rogen bonds, aromatic–aromatic interactions, etc.). In this way, the best possible docking 
structures were selected. Structures were visualized using DS Visualise v2.5.123 and the ob-
tained images were rendered using PovRay Raytracer v3.6.24 
RESULTS AND DISCUSSION 
The currently used loop-less D2 DA receptor model could not explain the 
binding affinities for a number of synthesized arylpiperazine ligands (Table I). 
Docking analysis suggested that these ligands are not able to fit into the existing 
binding site9 due to their size, and that they protruded into the extracellular loop 
(ecl) area of the D2 DA receptor. The importance of the ecls for accommodating 
high molecular weight GPCR ligands (peptides and proteins) is widely accep-
ted.25 Recent studies indicate the same could be true for low molecular weight li-
gands.22,26,27 
These findings emphasized that a new D2 model that includes the loops, 
should be constructed. In this study the focus was on the modeling of the extra-
cellular loops as they border the receptor binding site and could interact with li-
gand molecules.28 
Receptor loop modeling is a challenging task because, in contrast to the 
alpha helix or beta sheet, they do not fit into the defined 3D template and a care-
ful decision has to be made on how to differentiate between a myriad of possible 
conformations. 
Initial attempts to model the D2 receptor with loops in silico, using different 
existing templates, failed to produce a viable model. Construction of the ecls 
should be realized with care and guided by receptor-specific experimental data, 
rather than being performed in a high-throughput fashion and derived directly 
from the known crystal structure.29 
In order to solve this problem, computational methods, pharmacophore mo-
del generation and docking analysis, together with experimental results, were ap-
plied in this study. Apart from general ecl2 modeling, the aim of this study was 
to discover the ecl2 amino acid residues responsible for D2 DA receptor–ligand 
interactions. The pharmacophore model hypothesis predicts the type of receptor– 
–ligand interactions, thus ecl2 was modeled in a way to facilitate such interac-
tions, and docking analysis was employed to confirm that these interactions are 
de facto possible. 
Pharmacophore model generation requires a considerable ligand database, 
which was obtained from available literature sources.  
To facilitate the search, the molecular structure of the arylpiperazine ligands 
was divided into three distinct substructure motives: tail (arylpiperazine substruc-
ture), flexible linker and head part (usually the bulky aromatic group, see Fig. 1). 
The tail part of the ligand was kept fixed, while the linker and head part were 
subjected to variations in length and size. The tail part was fixed to 1-(2-me-
thoxyphenyl)piperazine since the interaction of this structural motive with the D2 
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DA receptor is well investigated.10 The length of the linker is crucial for the re-
ceptor–ligand interaction, since it positions the head of the ligand against the 
amino acid residues located in the extracellular loops of the receptor, and was 
therefore allowed to vary. In addition, differences in size, shape and functionality 
of the head were tolerated, allowing investigation of the influence of these mole-
cular diversities on the ligand binding affinity. More than 80 ligands were consi-
dered of which, 33 were selected for further investigation. Only ligands with a 
moderate to high affinity (Ki under 100 nM) were taken into consideration. 
 
Fig. 1. Schematic presentation of the proposed key interactions, 
generated by the pharmacophore hypothesis. 
Pharmacophore model generation was performed using Discovery Studio, as 
described. In total, 33 ligands were used to generate the pharmacophore model 
hypothesis. The obtained results are shown in Figs. 1 and 2. The pharmacophore 
model hypothesis suggests salt bridge formation between the protonated pipera-
zine nitrogen atom and the receptor, one or more aromatic interactions at the tail 
part of the ligand, together with a hydrogen bond between the oxygen atom of the 
methoxy group and the receptor. In the linker part, there is the possibility of 
hydrogen bond formation, while in the head part of the ligand, one or more in-
teractions were expected. These interactions could be of an aromatic nature or a 
hydrogen bond, depending of the chemical structure of the head of the ligand. 
Docking studies of these bulky ligands performed with the loop-less D2 DA 
receptor model could not explain the high affinities obtained in the binding stu-
dies. Therefore, it was hypothesized that some additional interaction with the out- 
-of-membrane receptor domain is involved. Molecular modeling that took into 
consideration interactions with ecl2 gave the best results. The ligands that can 
form additional aromatic type interaction or hydrogen bond in the head part can 
do so exclusively with amino acid residues located in the ecl2 region of the D2 
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DA receptor. Other proposed ligand–receptor interactions, such as the salt bridge 
formed between ASP80 and the protonated piperazine nitrogen, hydrophobic in-
teractions between PHE178, TRP182 and TYR212 and arylpiperazine, and hyd-
rogen bond formation between the 2-methoxy group oxygen and TYR212, are 
located in the transmembrane domain of the receptor molecule and are described 
in an earlier publication.9 
 
Fig. 2. Proposed pharmacophore hypothesis mapped on ligand 9. Proposed key interactions 
are shown as vectors and spheres, depicting the direction and space 
where a particular interaction is expected. 
Modeling of the ecl2 is described in the experimental part; particular atten-
tion was given to the orientation of the hydrophobic amino acid residues as good 
candidates to form aromatic interactions with ligands. 
The generated DA D2 receptor models with extracellular loops were tested 
using docking analysis until a satisfactory model that could explain the binding 
and activities of the selected ligands was obtained. 
In total, 11 literature ligands with activities ranging from 10 to 75 nM were 
selected for the docking analysis (Table II). It was decided to use ligands that had 
a significant affinity towards the D2 DA receptor while taking into account the 
structural diversity that could account for the proposed aromatic interactions and 
hydrogen bond formation with the ecl2 of the D2 DA receptor. 
Preliminary ligand docking was performed to allow the ligand to position 
itself inside the binding site. After a satisfactory ligand orientation had been ob-
tained (salt bridge formation between ASP80 and the protonated ligand nitrogen 
atom, aryl moiety positioned inside the hydrophobic pocket formed by PHE178, 
TRP182 and TYR212, one or more hydrogen bonds formed with SER149 and/or 
SER122), fixed atom constraints were applied on the ligand and receptor amino 
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acids backbone, excluding those in the ecls that were allowed to move freely. An 
additional docking run was executed whereby optimal positioning of the ecls 
amino acid residues was allowed. Finally, molecular dynamics calculations fol-
lowed by energy minimization were performed to remove any steric interactions. 
The obtained results are shown in Figs. 3–6. Thus, it is shown that the selected 
ligands can bind into proposed D2 DA receptor model and form interactions with 
the amino acid residues of the ecl2 loop, as required by the pharmacophore hypo-
thesis, while simultaneously concurring with recent findings (Fig. 3).12,28 
 
Fig. 3. Generated model of ecl2. Key amino acid residues responsible for interactions with the 
investigated ligands obtained by docking analysis are shown together 
with the conserved disulfide bond between ecl2 and ecl3. 
All the investigated ligands bind in a similar manner. The main features of 
the docked complexes are short salt bridges between the protonated nitrogen of 
the piperazine ligand and ASP80 and the number of interactions formed by the aryl 
tail section and the corresponding amino acids (PHE178, TRP182 and TYR212). 
Ligand 36 is the bulkiest ligand, with a high receptor affinity (Fig. 4). Its 
large hydrophobic head must be docked into the appropriate hydrophobic recep-
tor pocket that is formed by the amino acid residues LEU125, LEU126, ILE139, 
VAL146, PHE144, HIS189 and ILE190. The head of the ligand can form a num-
ber of hydrophobic interactions with the listed amino acid residues. Special atten-
tion should be given to PHE144 and HIS189, as they are in a range that could 
lead to the formation of edge-to-face (etf) interactions. These interactions to-
gether with the hydrogen bond formed with SER122 are responsible for the high 
ligand affinity. 
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Fig. 4. Docking results for li-
gand 36. Only key amino acid 
residues are shown for clarity. 
Ligands that have large hydrophobic groups in the head part (ligands 7, 8, 
23, 25, 32, 34 and 37) bind to the hydrophobic pocket that is formed in part by 
ecl2 (Fig. 5). This is the same pocket formed by PHE144, LEU125, ILE139, 
LEU126, VAL146 and ILE190, as in case of ligand 36. Docking analysis shows 
possible interactions formed by PHE144 (edge-to-face) and HIS189 on TM6 
(NH⋅⋅⋅Pi or CH⋅⋅⋅Pi) interactions with the ligand.  
Ligand 16 (Fig. 5) and ligands 13–15 and 17–19 are somewhat different as 
their head part contains groups capable of forming polar interactions or hydrogen 
bonds. In the case of these ligands, in addition to the already listed interactions, 
polar interactions with ASN141 in ecl2 could account for their activity. 
All ligands from Table II form one or more interactions with ecl2, based on 
their structure, and these interactions are responsible for their activity. For example, 
ligands 12, 13, 24, 36, 38–41 form aromatic interactions with hydrophobic amino 
acid residues. These interactions may include edge-to-face interactions with 
PHE144 and HIS189. Ligands 16–23 can form either hydrogen bonds or polar 
interactions with ASN141. Ligands 4–14, 26–35 and 42 can benefit from listed 
aromatic interactions and hydrogen bond with SER122. 
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Fig. 5. Ligands 27 (left) and 16 (right) docked into the D2 receptor. 
Only key amino acid residues are shown for clarity. 
Fig. 6. Ligand 1 docked into the proposed 
D2 model. Possible interactions with 
PHE144 and SER 149 are marked as lines. 
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The final test of the model was its ability to discriminate high affinity versus 
low affinity ligands. The test was performed on compounds homologous to the 
active ligands (Table II) but with significantly lower D2 DA receptor affinity. 
Chemical structures alongside the affinity data of these compounds are presented 
in Table III. 
The results of docking analysis are shown in Fig. 7. Ligand 38 is similar to 
36, yet its binding affinity is 10-fold lower. The ligand cannot optimally fit into 
the proposed pocket, formed by elc2 amino acid residues, as multiple bump 
interactions with SER122 and HIS189 are observed (Fig. 7, left), furthermore due 
to different ligand orientation hydrogen bound with SER122 is lacking. 
 
Fig. 7. Docking results for the low affinity arylpiperazine ligands 38 (left) and 40 (right). Only 
key amino acid residues are shown. Bump interactions are marked as dashed lines. 
Ligand 40 is similar to ligand 10. The increase in overall length of ligand 40 
is a key factor for its ten-fold decrease in affinity. Being both long and rigid, 
ligand 40 suffers from unfavorable steric interactions with amino acid residues in 
the receptor ecl2. Due to its inability to fit into the binding site, all the observed 
key interactions have longer distances. Most notably, the salt bridge with ASP80 
is elongated by 1 Å, and the hydrogen bonds with SER122 and SER149 are con-
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siderably longer (3.57 and 3.92 Å compared to 2.47 and 2.98 Å in ligand 10, Fig. 
7, right). 
Similar factors can explain the seven-fold decrease in affinity of 39 vs. 21. In 
the case of ligand 39, the introduction of the furan ring into the head segment 
leads to a loss in binding affinity, due to steric interaction between the chlorine 
atom and ASN141. This steric interaction pushes the ligand down into the bind-
ing site, making the key interactions with ASP80 and SER122 longer by 1 Å 
(Fig. 8). 
Fig. 8. Docking result for the low affinity 
arylpiperazine ligand 39. Only key amino 
acid residues are shown. 
Finally, the proposed D2 DA receptor model was used to explain the binding 
affinities of the ligands shown in Table I. Docking results showed that ligands 1 
and 2 forms multiple aromatic interactions with PHE144, LEU125, LEU126 and 
VAL146 (Fig. 6). Ligands 3 and 4, which cannot form aromatic interactions, still 
benefit from hydrogen bonds formation or polar interactions with ASN141 in ecl2. 
CONCLUSION 
The primary aim of the current study was to provide a new D2 DA receptor 
model that includes ecls that is capable of explaining existing experimentally ob-
tained affinity data for bulky arylpiperazine type ligands. 
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Modeling ecls residues in silico is highly speculative as they are located in 
the part of the molecule that cannot be directly derived from the existing struc-
tural templates. Although the recent publishing of the crystal structure of the D3 
DA receptor17 is a significant step forward, it was decided to employ the exist-
ing, experimentally proved D2 DA receptor model, which was made by combi-
ning in silico methods and experimental data and proved by experimental re-
sults.9–11 Still, the exact structure of the D2 DA receptor remains unknown and, 
therefore, every model that can explain experimental data should be considered. 
The model described in this study can explain the DA receptor binding properties 
of arylpiperazine classes of ligands; hence, it could be of great value for virtual 
screening studies. 
The employed approach in modeling ecls was twofold. First, a pharmaco-
phore model was constructed using a number of different ligands, having a com-
mon arylpiperazine moiety. This model indicated to a number of possible interac-
tions between a ligand and the receptor, including interactions in the ecl2 part. 
Based on these assumptions, the ecls were modeled. Then, docking analysis was 
performed to position the ligand inside the receptor-binding site, until all known 
interactions were established. The ecl2 residues were then adjusted to form other 
interactions predicted by the pharmacophore model. Further energy minimization 
and molecular dynamics were used to refine the obtained results. 
During the modeling process, a number of key amino acid residues located 
in the ecl2 that could form interactions with ligands were observed. These inter-
actions, which lead to high ligand affinity, included aromatic interactions with 
PHE144, LEU125, LEU126, VAL146 and ILE190 and polar interactions with 
ASN141. Aromatic interactions are most likely edge-to-face type with PHE144 
or CH···Pi (or NH···Pi) interactions with HIS189. Polar interaction with ASN135 
could also be responsible for the high binding affinity of ligands with the corres-
ponding functional groups. The size of the ligand is important. Short ligands do 
not benefit from interactions with ecl2, while long ones suffer from steric interac-
tions with amino acid residues in the loop. The head part of the ligand should 
have at least one aromatic ring, but systems with two or more aromatic rings are 
well tolerated unless the maximum allowed length of the ligand is attained. High 
affinity could be achieved by aromatic interactions alone, or together with polar 
interactions. Ligands with halogen atoms or polar groups have affinities compa-
rable with those of their aromatic analogues. The linker part of the ligand should 
be as flexible as possible, since its primary function is to allow the optimum po-
sitioning of the head part into the space formed by the ecl2.  
For the sake of verification of the proposed D2 DA receptor model, further 
work on the target-driven synthesis of new ligands that can distinguish between 
the proposed molecular interactions are necessary. The final goal is to obtain a 
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workable D2 DA receptor model that will facilitate the design of new specific 
dopaminergic drugs. 
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Друга екстрацелуларна петља допаминског D2 рецептора је есенцијални део везивног 
места рецептора. Да би се дефинисала горња страна везивног места, она мора да се савије 
надоле, и оријентише ка трансмембранском домену рецептора. У овом раду описан је процес 
моделовања друге екстрацелуларне петље допаминског D2 рецептора и њене интеракције са 
арилпиперазинским лигандима. За моделовање је коришћен Accelrys Discovery Studio пакет 
програма. Предложени модел је тестиран докинг анализом литературно доступних лиганада 
и поређењем добијених резултата са њиховим афинитетом везивања за D2 рецептор. Одре-
ђени су амино-киселински остаци који ступају у интеракције са лигандима. Кључне интер-
акције су дефинисане и упоређене са афинитетима лиганада према рецептору како би се 
предложеним моделом објасниле разлике у експерименталним резултатима. Наша истражи-
вања су показала да друга екстрацелуларна петља допаминског D2 рецептора може ступати 
у различите интеракције са арилпиперазинским лигандима које између осталих укључују 
хидрофобне, ароматичне интеракције али и водноничне везе. Ова сазнања, у комбинацији са 
предложеним моделом D2 рецептора, који укључује екстрацелуларне петље, могу бити од 
велике користи приликом будућег дизајна нових допаминергичких лиганада. 
(Примљено 28. октобра 2011) 
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